Latest diabetic neuropathy Stories
Broad Label Indicated for Peripheral Neuropathic Pain in Non-Diabetic Adults Conference Call Scheduled Friday, March 20 at 9am ET SAN MATEO, Calif., March 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
Transplanting cells that replenish blood vessels can also restore nerve function in an animal model of diabetic neuropathy, Emory researchers have found.
More than 20 million Americans are living with diabetes, and that number is expected to increase by more than 5 million by 2010.
Itâ€™s now easier to know who should be tested for a common nerve disorder, when they should be tested, and how.
DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation announced today that the last subject in the Phase IIb Study is scheduled to complete treatment on November 25, 2008.
Sangamo BioSciences, a developer of novel DNA-binding proteins for therapeutic gene regulation and modification, has announced top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase II clinical studies from its ZFP therapeutic program to develop SB-509 for diabetic neuropathy.
RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN).
XTL Biopharmaceuticals, a developer of therapeutics for the treatment of diabetic neuropathic pain and hepatitis C virus, has announced that the last patient randomized into the Bicifadine Phase IIb clinical trial for the treatment of diabetic neuropathic pain has completed the study.
RICHMOND, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.